Ask about this productRelated genes to: NFKB1 Blocking Peptide
- Gene:
- NFKB1 NIH gene
- Name:
- nuclear factor kappa B subunit 1
- Previous symbol:
- -
- Synonyms:
- KBF1, p105, NFKB-p50, p50, NF-kappaB, NFkappaB, NF-kB1
- Chromosome:
- 4q24
- Locus Type:
- gene with protein product
- Date approved:
- 1991-11-14
- Date modifiied:
- 2019-04-23
Related products to: NFKB1 Blocking Peptide
Related articles to: NFKB1 Blocking Peptide
- Anxiety is one of the most common mental health disorders today, often leading to panic, restlessness, and tension. Conventional treatments can cause adverse effects, prompting interest in plant-based alternatives. Glycowithanolides from (WSGs) have demonstrated neuroprotective effects, but their role in anxiety management remains underexplored. This study evaluates the anxiolytic potential of WSGs using an integrated computational approach combining pharmacokinetic profiling, network pharmacology, molecular docking, and molecular dynamics (MD) simulations. Eleven WSGs exhibited favorable blood-brain barrier permeability and drug-likeness, complying with Lipinski's Rule of Five. Network pharmacology revealed key interactions between WSGs and anxiolytic pathways such as cAMP, Ras, and calcium signaling, as well as addiction-related pathways. Genes like GRIN1, CHRM1, NFKB1, and HDAC2 emerged as potential targets, with GRIN1 identified as the central hub. Molecular docking of the WSGs with GRIN1 (PDB ID: 5EWM) indicated strong binding affinities, and the best-scoring ligand-receptor complex was further evaluated through MD simulations to assess stability and interactions. Results suggest strong binding of WSGs to GRIN1 and indicate a potential modulatory role; however, the proposed mechanism remains hypothesis-generating and requires experimental validation. Overall, this study highlights the therapeutic promise of glycowithanolides in managing anxiety disorders and offers a mechanistic basis for future experimental validation. - Source: PubMed
Publication date: 2026/05/11
Rahaman MonosizGhosh Sourav - Tamoxifen (TAM) resistance limits favorable outcomes in patients with breast cancer. Bioinformatics results suggest that the miR-548as-5p/nuclear factor kappa B1 (NF-κB1) axis may regulate TAM resistance. The aim of this study was to investigate the role of the miR-548as-5p/NF-κB1 axis in TAM resistance. - Source: PubMed
Publication date: 2026/05/13
Chen XuTao MengZhuang YuZhao JunyiYao ChangLu Dongchen - As cannabis use continues to rise among people with HIV (PWH), understanding its impact on immune function in this population is becoming increasingly important. To provide new insights on how cannabis modulates immune function, we analyzed single-nucleus multi-omic profiles of peripheral blood mononuclear cells (PBMCs) from PWH to characterize the changes in gene expression and chromatin accessibility associated with chronic cannabis exposure. We identified numerous differentially expressed genes (DEGs) between cannabis users and non-users in each cell type, approximately half of which were unique to individual cell types. Changes in pro- and anti-inflammatory gene expression associated with cannabis use are dependent on cell lineage and type. We identified hundreds of differential chromatin accessibility regions in each cell type, including -regulatory elements correlated with cell-type-dependent DEGs (e.g. in CD4+ T cells and in classical monocytes). Multiple cannabis-associated transcription factors (e.g., , and ) emerge as regulators of the differentially expressed inflammatory genes. Furthermore, cannabis altered the communication between classical monocytes and lymphocytes. These findings indicate that cannabis-induced immunomodulatory effects are profound, dynamic and complex among cell types and that transcriptional changes are regulated at least in part by epigenetic mechanisms. - Source: PubMed
Publication date: 2026/02/27
Li MingruiAsam KesavaDuan XiaokePage Grier PHu YingMartinez ClaudiaCohen Mardge HArchin Nancie MValizadeh AmirHancock Dana BJohnson EricAouizerat Bradley EXu Ke - Pulmonary fibrosis (PF) is a progressive, life-threatening disease characterized by excessive extracellular matrix deposition, leading to impaired lung function. Despite advancements in therapeutic interventions, the development of effective antifibrotic agents with minimal side effects remains a significant challenge. Solanum xanthocarpum (SLM) is a traditional medicinal plant used in multiple Ayurvedic formulations effective against cough, asthma, and inflammation. However, its molecular mechanisms are largely unexplored. - Source: PubMed
Publication date: 2026/05/11
Vithalkar Megh PravinB Bharath HB KrishnaprasadNayak Usha YM Fayaz SB SathyanarayanaNayak Yogendra - This study combined serum pharmacochemistry, metabolomics, and network pharmacology to uncover potential active components and mechanisms of Shenling Baizhu Powder (SLBZP) in treating ulcerative colitis with spleen deficiency and dampness stagnation (UC-SDDS), providing scientific evidence for its efficacy. Pharmacodynamic investigations demonstrated that SLBZP exhibits substantial anti-inflammatory properties and confers protection to the intestinal barrier in UC-SDDS rat models. Further, 16 active components and six core targets (BCL2, NFKB1, TNF, IL6, AKT1, CASP3) were obtained using serum pharmacochemistry and network pharmacology. Twenty-six differential metabolites in serum and 25 differential metabolites in urine were identified using untargeted metabolomics analyses. Subsequently, nine active components (butein, calycosin-7-o-β-d-glucoside, glabridin, isochlorogenic acid B, naringenin chalcone, naringenin, neoliquiritin, oroxyloside, and vanillic acid) were identified from SLBZP for treating UC-SDDS by integrating network pharmacology and chinmedomics. Molecular docking and dynamics simulation revealed that these compounds exhibit superior binding affinities to six core targets. Finally, the expression levels of AKT1, p-AKT1, mTOR, Caspase 3, TLR2, TLR4, ERK1/2, STAT1, MyD88, NFκB, and BCL2 in colon tissues were detected in UC-SDDS rats treated with SLBZP. The study showed that SLBZP effectively treats UC-SDDS rats by modulating multiple components, targets, and pathways using serum pharmacochemistry, network pharmacology, and metabolomics. - Source: PubMed
Shen BixinYang ZhenyuPan YixiaoYang WeijinChen Jing